Entity

Time filter

Source Type


Krul E.S.,Solae LLC | Lemke S.L.,Monsanto Corporation | Mukherjea R.,Solae LLC | Taylor M.L.,Monsanto Corporation | And 6 more authors.
Prostaglandins Leukotrienes and Essential Fatty Acids | Year: 2012

Objective: The purpose of this randomized, controlled, parallel group study was to characterize the relationships between dosages of stearidonic acid (SDA) and eicosapentaenoic acid (EPA), and incorporation of EPA into red blood cell (RBC) membranes over time. Methods: Healthy subjects (n=131) received capsules with placebo (safflower oil), SDA (0.43, 1.3, 2.6, or 5.2. g/d) or EPA (0.44, 1.3, or 2.7. g/d) for 12 weeks. RBC fatty acids were analyzed biweekly. Results: RBC %EPA increased in all EPA and SDA groups (p<0.02 vs. control) except the 0.43. g/d SDA group (p=0.187). For theoretical intakes of EPA of 0.25, 0.5, and 0.89. g/d, the amounts of SDA needed to achieve equivalent RBC EPA enrichment were 0.61, 1.89, and 5.32. g/d (conversion efficiencies of 41%, 26%, and 17%), respectively. Conclusions: SDA increased RBC %EPA in a dosage and time-dependent manner at intakes as low as 1.3. g/d. © 2011 Elsevier Ltd. Source


Maki K.C.,Provident Clinical Research Biofortis North America | Lawless A.L.,Provident Clinical Research Biofortis North America | Kelley K.M.,Provident Clinical Research Biofortis North America | Dicklin M.R.,Provident Clinical Research Biofortis North America | And 2 more authors.
Prostaglandins Leukotrienes and Essential Fatty Acids | Year: 2011

Treatment with prescription omega-3-acid ethyl esters (POM3) reduces triglycerides (TG) and TG-rich lipoprotein particles, but has been associated with increased fasting glucose (2-6. mg/dL). This double-blind, randomized, controlled crossover trial in 19 men and women with hypertriglyceridemia (fasting TG ≥150 and ≤499. mg/dL) examined lipid responses and indices of insulin sensitivity and secretion following a liquid meal tolerance test. Six weeks treatment with POM3 vs. corn oil resulted in significant lower mean fasting (-50.1. mg/dL, p<0.001) and postprandial TG (-76.1. mg/dL, p<0.001), higher mean fasting glucose (2.8. mg/dL, p=0.062), reduced mean disposition index (2.1 vs. 2.4, p=0.037), and no change in the median Matsuda composite insulin sensitivity index (3.3 vs. 3.2, p=0.959). These results suggest that POM3 slightly reduces pancreatic Β-cell responsiveness to plasma glucose elevation, which may contribute to the rise in fasting glucose sometimes observed with POM3. © 2011 Elsevier Ltd. Source

Discover hidden collaborations